← All organizations
Highest phase reached
Phase 3
First clinical trial
Dec 1, 2004First marketed drug
Oct 17, 2012First NDA
Oct 17, 2012Last known activity
Aug 27, 2021
Timeline
1990s
- Jun 1, 1991
Oxurion NV.— Founded
2010s
- Oct 17, 2012
ocriplasmin— Marketing Organization
- Oct 17, 2012
ocriplasmin— NDA Organization
Drugs by trial phase (13 distinct, 31 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (9 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Arterial Occlusive Diseases
- Diabetic Retinopathy
- Disease Progression
- Edema
- Eye Diseases
- Macular Degeneration
- Macular Edema
- Neoplasms
- Retinal Diseases
- Retinal Perforations
- Retinal Telangiectasis
- Stroke
- Telangiectasis
- Thromboembolism
- Thrombosis
- Tissue Adhesions
- Venous Thrombosis
- Vitreous Detachment
- Wet Macular Degeneration
Marketed drugs (1)
Recent trials (38)
- NCT05063734Lead sponsorPhase 2Aug 27, 2021
- NCT05063734Study directorPhase 2Aug 27, 2021
- NCT04527107Lead sponsorPhase 2Jul 31, 2020
- NCT04527107Study directorPhase 2Jul 31, 2020
- NCT04300881CollaboratorPhase 2Oct 4, 2019
- NCT03669393Lead sponsorPhase 2Sep 30, 2018
- NCT03666923Study directorPhase 1Sep 30, 2018
- NCT03669393Study directorPhase 2Sep 30, 2018
- NCT03666923Lead sponsorPhase 1Sep 30, 2018
- NCT03511898Study directorPhase 1May 18, 2018
- NCT03511898Lead sponsorPhase 1May 18, 2018
- NCT03499223Lead sponsorPhase 2Apr 20, 2018
- NCT03071068Study directorPhase 2Dec 1, 2016
- NCT03071068Lead sponsorPhase 2Dec 1, 2016
- NCT02681809Lead sponsorPhase 2Dec 1, 2015
Details
- Founded
- Heverlee, BE Jun 1, 1991
- First NDA
- Oct 17, 2012
- Last known activity
- Aug 27, 2021